Current strategies against invasive fungal infections in patients with aplastic anemia, strong power and weak weapon, a case report and review of literature

Omid Reza Zekavat a,b, Ali Amanati c,d,* Fazl Saleh b, Babak Abdolkarimi b, Gholamreza Fathpour b, Parisa Badiee c, Bita Geramizadeh e

a Hematology Research Center, Namazi Hospital, Karimkhang Zand St., Shiraz 7193711351, Iran
b Department of Pediatric Oncology, Amir Oncology Hospital, Farhang Shahr, Shiraz 7187915998, Iran
c Professor Alborzi Clinical Microbiology Research Center, Namazi Hospital, Karimkhang Zand St., Shiraz 7193711351, Iran
d Department of Pediatric Infectious Diseases, Namazi Hospital, Karimkhang Zand St., Shiraz 7193711351, Iran
e Department of Pathology Transplant Research Center, Namazi Hospital, Karimkhang Zand St., Shiraz 7193711351, Iran

Article info
Article history:
Received 26 February 2016
Accepted 7 March 2016
Available online 8 March 2016

Keywords:
Anemia, Aplastic
Mucormycosis
Aspergillosis
Antifungal agents

A B S T R A C T

We report an 18 year old boy with Aplastic anemia complicated by serious fungal rhinosinusitis. Despite prompt treatment and early repeated surgical debridements, he died after about more than 6 weeks of hard challenges with fungal infections. Current strategies against invasive fungal infections (IFIs) in patients with Aplastic anemia may be inadequate for the management of serious complications. Antifungal prophylaxis is highly recommended in pre-transplant period for severe form of Aplastic anemia.

© 2016 The Authors. International Society for Human and Animal Mycology. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

1. Introduction

Aplastic anemia is characterized by bone marrow failure and marked decrease in all marrow elements. In severe form of Aplastic anemia, rapid bone marrow transplantation after primary workup is life saving; however, protected environment and prevention of opportunistic infections may be difficult in these cases [1].

Most patients with Aplastic anemia experience repeated episodes of infection during their life. Gram positive (predominantly gram-positive cocci) and gram negative organisms (especially Multi-Drug Resistance (MDR) negative bacilli) are the most common causes of infections, but IFIs remain the main cause of death and increase the mortality among respective patients [2,3]. Aspergillosis and Mucormycosis are the most common mold infections in patients with Aplastic anemia [2].

In reported case series by Valera (2011), in 32 patients with acute invasive fungal rhinosinusitis, all deaths were reported among patients with Aplastic anemia despite surgical debridement and systemic antifungal therapy [4].

Severe neutropenia predisposes these patients to more severe forms of IFIs with a wide range of clinical manifestations. Gastrointestinal [5], upper air way [6], musculoskeletal [7] cardiac [8], renal [9], disseminated infection [10] and Rhinocerebral/sino-orbital/rhinosinusitis [11] among the most common reported manifestations of IFIs in patients with Aplastic anemia. Of these conditions, the last one is the most serious and fatal [4]. We report on a serious fungal infection in a case of Aplastic anemia and offer an appropriate strategy for the treatment and prevention in such patients.

2. Case

An 18 year old boy, known case of Aplastic anemia since 7 years ago, admitted with severe headache and fever in emergency ward. He was a candidate for bone marrow transplantation because of standard treatment failure that included corticosteroid, anti-thymocyte globulin (ATG) and cyclosporine, and put on in transplant waiting list. He had frequently received blood and platelet transfusion due to low hemoglobin (Hb) level and often nose bleeding.

On admission, he had severe leukopenia [white blood cell count (WBC): 100 (without cell differentiation)], anemia (Hb: 6.5) and severe thrombocytopenia (platelet count: 6000). Erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) were 130 and 48, respectively.

After initial assessment, broad spectrum antibiotics (Piperacillin-Tazobactam) were started for him. Two days later, he developed pain, swelling and redness of the right side of face.
Gradually, the patient exhibited high grade fever, chills, intolerable headache and periodic disorientation, so due to poor clinical response, an antifungal agent (Amphotericin-B deoxycholate) was added to his antibiotic regimen on fifth day of admission.

In serial physical examination (after primary unilateral face swelling and cellulitis), he developed necrotic lesions in soft and hard palate followed by nasal septum, right alar groove and right nasolabial fold necrosis.

Tomography scan (CT scan) was requested, which revealed right maxillary and ethmoidal sinus involvement (Fig. 1).

Surgical consult has been also requested for diagnostic aspiration and evaluation for surgical debridement. Despite low platelet count, after receiving single donor platelet transfusion, right maxillary sinus debridement was performed and samples were sent for pathology. Fungal elements similar to mucoral hyphae were reported by pathologist.

After primary aspiration, right maxillary sinus debridement was performed during single donor platelet transfusion and samples were sent for pathology. Upon early surgical debridement and short time clinical improvement, all signs and symptoms exacerbated again after few days. Caspofungin was added and second surgical debridement planned 10 days after the first one, and has been organized for short interval surgical sinus debridements during platelet transfusion, till it becomes completely clear.

In the next surgical debridement tissue samples were cultured on Sabouraud dextrose agar (Merck, Darmstadt, Germany) and also examined for Aspergillus and Candida DNA by real time polymerase chain reaction (PCR) and Mucoral by nested PCR [12,13]. Bacterial culture and specimen were sent for microbiology and pathology, respectively.

Other successful debridements were done twice in short intervals. Finally, all involved sinuses, nasal cavity and overlying soft tissue were completely removed by anterior and posterior ethmoidectomy and sphenoidectomy. Also, posterior part of septum was removed. Detailed information about time and results of clinical samples were included in Table 1.

Adjuvant therapy with gamma interferon 100 μg/day in combination with Granulocyte-colony stimulating factor (G-CSF) [300 μg/day primarily and then with full dose of 600 μg/day in two divided doses] was added to the broad antibacterial and antifungal treatments.

Other assessments including blood culture and urine culture were negative and chest x-ray, abdominal ultrasonography and echocardiography were normal in primary evaluations. However in serial chest x-rays, early possible signs of pulmonary involvement detected in about 3 weeks after his admission (Fig. 2).

Bilateral well-circumscribed ground-glass gray opacities were detected in these chest x-rays confirmed by spiral chest CT scan (Fig. 3).

Our further investigation into fungal infection revealed positive Mucormycosis, Aspergillus and Candidiasis by PCR and positive fungal culture for Aspergillus flavus and Candida albicans in repeated debridement (Fig. 4C).

No positive culture was obtained from Mucormycosis. During admission, the patient had several positive blood cultures (Table 2). His antibiotic was changed based on antibacterial susceptibility test. Sinus debridement during antifungal treatment was done in four times, but the patient’s condition gradually worse and eventually expired.

![Fig. 1. Para-nasal CT scan (PNS CT) of patient before second surgical debridement which revealed complete right maxillary sinus opacity and involvement of bilateral ethmoid sinuses without any obvious bone destruction.](image-url)

### Table 1
Summary information of repeated debridement and direct mycology test results.

| Date         | Pathology | Tissue PCR Aspergillus | Tissue PCR Mucormycosis | Tissue PCR Candida | Culture |
|--------------|-----------|------------------------|-------------------------|--------------------|---------|
| First surgical debridement | 20 July 2015 | Mucormycosis | Not sent | Not sent | Not sent |
| Second surgical debridement | 30 July 2015 | Mucormycosis | + | Neg. | Neg. |
| 3rd surgical debridement | 7 August 2015 | Mucormycosis | + | Neg. | +|
| 4th surgical debridement | 21 August 2015 | Mucormycosis | + | + | +** |

*Admission date: 13 July 2015.
**Aspergillus Flavus.
3. Discussion

Frequent episodes of profound and prolonged neutropenia, aggressive chemotherapy, exposure to fungal spores in non protected environment and consequently preadmission colonization with fungal agents and high risk condition such as Aplastic anemia and Acute Myeloid Leukemia (AML) are some of typical examples that increase the risk of IFIs [14].

Along with high clinical suspicions, early diagnosis and treatment; multidisciplinary approach against IFIs significantly reduced mortality [15]. Constantly low absolute neutrophil count (ANC), lack of standard and secure control measures such as high-efficiency-particulate-air (HEPA) in many centers and progressive nature of certain fungal infections such as Mucormycosis; all are important obstacles to our attempts toward controlling fungal infections in these patients.

Despite very low platelet count (less than 6 \times 10^3/microliter), our patient underwent four times of successful surgical debridement, during continuous single donor platelet transfusions, without any hemostatic complications. In each times he was referred to operation room after preparation of donor platelet for infusion during surgical debridement (Fig. 5).

Along with severe neutropenia, prolonged hospital stay and broad spectrum antibiotic therapy with damaged skin and mucosal barriers and presence of indwelling catheters predisposed our patient to colonization and infection with hospital acquired multidrug resistant organisms. Such patients are at greater risk for acquisition of MDR gram positive and gram negative organisms such as Acinetobacters, Methicillin-resistant Staphylococcus aureus (MRSAs) and vancomycin-resistant Enterococcus (VREs) [2]. This is an important point in management of these patients that should also take into consideration such as our patient which finally complicated by VRE Bacteremia.

Diagnostic misconception based on primary clinical presentation is one of the other important challenges in the management of IFIs in severe neutropenic patients.

Although rhinocerebral/sino-orbital/rhinosinusitis IFIs are frequently considered as clinical manifestation of Mucormycosis, it is critical to obtain proper tissue specimens for culture and biopsy, whenever possible; given the similar clinical presentations of Aspergillosis. Mucoral family is difficult to cultivate and sensitivity of culture for this family was reported around 50% [16] and thus other diagnostic modalities (histopathological characteristics and molecular test) should be considered, if needed.

Co-detection of multiple fungi also is not an uncommon event in severe neutropenic patients and accurate diagnosis can help correct decision making in choosing proper antifungal regimen.

Although fever-driven approach for empirical antifungal therapy; based on existing guidelines is currently applied in many hematology oncology centers worldwide, but this issue continues to be a challenge and IFIs still is one of the leading causes of mortality and morbidity in neutropenic patients with persistent fever [17].

Other different treatment approaches either pre-emptive (diagnostic-driven approach) or targeted therapy also may be used, according to radiological findings, clinical symptoms and mycology test results. These approaches have been tested by researchers in different populations and in various settings in neutropenic patients.

Despite the fact that implementation of these strategies substantially has reduced the burden of IFIs in high risk patients, antifungal prophylaxis still is an important strategy for the prevention of IFIs in certain circumstances.

Currently, there is no recommendation about starting antifungal prophylaxis for patients with Aplastic anemia (as a one of
the high risk groups) in the latest guideline of Infectious Diseases Society of America (IDSA, 2011) and 4th European Conference on Infections in Leukemia (ECIL-4, 2011) [18,19].

Although prompt diagnosis and early transplantation seem to be the only reliable modality in the protection of such patients against serious infectious complications (mainly IFIs), but based on our experience and also other similar reports we recommend that patients with Aplastic anemia receive anti-mold prophylaxis during the period of profound and prolonged neutropenia (ANC less than 500/ microliter) instead of other proposed strategies for the management of patients within pre-transplantation period. It should be noted that in the case of Aspergillosis indirect tests such as galactomannan and molecular tests have been improved our diagnostic power for early detection of IFIs due to Aspergillosis. Yet, there is no standard diagnostic test for early detection of Mucormycosis except histopathology and culture [20].

Also, in centers with high incidence of Mucormycosis, it seems better to better that use an agent which is active against both Mucormycosis and Aspergillosis for prophylaxis.

**Conflict of interest**

The authors did not have any financial or other relationships, which could be regarded as a conflict of interest.
Acknowledgments

Study concept and design: O.R. Zekavat, A. Amanati. Acquisition of data: A. Amanati, F. Saleh, G Fathpour, B. Abdolkarimi. Drafting the manuscript: A. Amanati, F. Saleh. Molecular tests provider: P. Badiee. Pathology report: B. Geramizadeh. Our thanks go to Hassan Khajehei, PhD, for copy editing of the report.

References

[1] M. Miano, C. Dufour, The diagnosis and treatment of aplastic anemia: a review, Int. J. Hematol. (2015) 1–9.
[2] J.M. Valdez, P. Scheinberg, N.S. Young, T.J. Walsh (Eds.), Infections in patients with aplastic anemia, in: Seminars in hematology, Elsevier, 2009.
[3] M. Weinberger, I. Elattar, D. Marshall, S.M. Steinberg, R.L. Redner, N.S. Young, et al., Patterns of infection in patients with aplastic anemia and the emergence of Aspergillus as a major cause of death, Medicine 71 (1) (1992) 24–43.
[4] F.C. Valera, T. do Lago, E. Tamashiro, C.C. Yassuda, F. Silveira, W.T. Anselmo-Lima, Prognosis of acute invasive fungal rhinosinusitis related to underlying disease, Int. J. Infect. Dis. 15 (12) (2011) e841–e844.
[5] M. Pajpani, R. Webb, Lingual necrosis caused by mucormycosis in a patient with aplastic anemia: case report, Br. J. Oral. Maxillofac. Surg. 52 (10) (2014), e144-6. Epub 2014/10/11.
[6] M. Nagasawa, S. Itoh, D. Tomizawa, M. Kajiwara, T. Sugimoto, J. Kumagai, Invasive subglottal aspergillosis in a patient with severe aplastic anemia: a case report, J. Infect. 44 (3) (2002) 198–201, Epub 2002/07/09.
[7] R. Le Calloch, J.C. Ianotto, G. Guillerm, J.M. Tonnelier, Fungal arthritis of the hip in patient with aplastic anemia. BMJ case reports. 2013. Epub 2013/08/16.
[8] I. Sasmaz, G. Leblebisatan, B. Asitmen, F. Binokay, N. Tunali, Y. Kiline, Cardiac mucormycosis in a child with severe aplastic anemia: a case report, Pediatr. Hematol. Oncol. 23 (5) (2006) 433–437, Epub 2006/05/27.
[9] R. Sharma, G. Shivanand, R. Kumar, S. Prem, H. Kandpal, C.J. Das, et al., Isolated renal mucormycosis: an unusual cause of acute renal infarction in a boy with aplastic anaemia, Br. J. Radiol. 79 (943) (2006) e19–e21, Epub 2006/07/11.
[10] C.E. Gonzalez, D.R. Couriel, T.J. Walsh, Disseminated zygomycosis in a neutropenic patient: successful treatment with amphotericin B lipid complex and granulocyte colony-stimulating factor, Clin. Infect. Dis. 24 (2) (1997) 192–196.
[11] M. Gamaletsou, N. Sipsas, E. Roulides, T. Walsh, Rhino-orbital-cerebral mucormycosis, Curr. Infect. Dis. Rep. 14 (4) (2012) 423–434.
[12] F. Badiee, B. Gandomi, G. Sahz, B. Khodami, M. Choopanizadeh, H. Jafarian, Evaluation of nested PCR in diagnosis of fungal rhinosinusitis, Iran. J. Microbiol. 7 (1) (2015) 62.
[13] F. Badiee, A.A. Amirghofran, M.G. Nour, Evaluation of noninvasive methods for the diagnosis of fungal endocarditis, Med. Mycol. 52 (5) (2014) 530–536.
[14] M. Stanzani, R.E. Lewis, M. Fiacchini, P. Ricci, F. Tumsetto, P. Viale, et al., A risk prediction score for invasive mold disease in patients with hematological malignancies, PLoS One (2013);
[15] E.J. Goldstein, B. Spellberg, T.J. Walsh, D.P. Kontoyiannis, J. Edwards, A.S. Ibrahim, Recent advances in the management of mucormycosis: from bench to bedside, Clin. Infect. Dis. 48 (12) (2009) 1743–1751.
[16] M.M. Roden, T.E. Zaat, W.L. Buchanan, T.A. Knudsen, T.A. Sarkisova, R.L. Schaufele, et al., Epidemiology and outcome of zygomycosis: a review of 929 reported cases, Clin. Infect. Dis. 41 (5) (2005) 634–653.
[17] V.R. Bhattacharya, G.M. Viola, A. Ferrajoli, Invasive fungal infections in acute leukemia, Ther. Adv. Hematol. 2 (4) (2011) 231–247.
[18] A.G. Freifeld, E.J. Bow, K.A. Sepkowitz, M.J. Boeckh, J.I. Ito, C.A. Mullen, et al., Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America, Clin. Infect. Dis. 52 (4) (2011) e56–e93.
[19] A.H. Groll, E. Castagnola, S. Cesaro, J-H. Dalle, D. Engelhard, W. Hope, et al., Fourth European Conference on Infections in Leukaemia (ECIL-4): guidelines for diagnosis, prevention, and treatment of invasive fungal diseases in paediatric patients with cancer or allogeneic haemopoietic stem-cell transplantation, Lancet Oncol. 15 (8) (2014) e327–e340.
[20] O. Cornely, S. Arikan-Akdagli, E. Dannaoui, A. Groll, K. Lagrou, A. Chakrabarti, et al., ESCMID and ECMM joint clinical guidelines for the diagnosis and management of mucormycosis 2013, Clin. Microbiol. Infect. 20 (s3) (2014) 5–26.